TQ B3139

Drug Profile

TQ B3139

Alternative Names: TQ-B3139

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 19 Jul 2017 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03099330)
  • 10 Apr 2017 Preclinical trials in Cancer in China (PO)
  • 10 Apr 2017 Chia-tai Tianqing Pharmaceutical plans a phase I trial for Cancer in China (NCT03099330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top